Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice.
about
The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's DiseaseEarly alterations of brain cellular energy homeostasis in Huntington disease modelsReversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregationOld Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative DisordersA huntingtin-mediated fast stress response halting endosomal trafficking is defective in Huntington's disease.Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis)The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's diseaseNormal huntingtin function: an alternative approach to Huntington's diseaseA novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's diseaseHomeostatic adaptations in brain energy metabolism in mouse models of Huntington diseaseA broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice.Metabolism in HD: still a relevant mechanism?Inhibition of mitochondrial protein import by mutant huntingtinReview: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibitionUnbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolismDecreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulationMitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survivalPlants and phytochemicals for Huntington's diseaseInhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's diseaseMetabolic profiling for the identification of Huntington biomarkers by on-line solid-phase extraction capillary electrophoresis mass spectrometry combined with advanced data analysis tools.Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genesComposite primary neuronal high-content screening assay for Huntington's disease incorporating non-cell-autonomous interactions.Therapeutic Strategies in Huntington's DiseasecAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in DrosophilaCREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expressionRegulation of miR-146a by RelA/NFkB and p53 in STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington's diseaseMetabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ.Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin.Abnormal motor cortex plasticity in premanifest and very early manifest Huntington diseaseProtection by glia-conditioned medium in a cell model of Huntington diseaseDownregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients.Targets for future clinical trials in Huntington's disease: what's in the pipeline?4-Phenylbutyrate attenuates the ER stress response and cyclic AMP accumulation in DYT1 dystonia cell models.Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.Grb2 is regulated by foxd3 and has roles in preventing accumulation and aggregation of mutant huntingtinTranscription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspectiveHD CAG-correlated gene expression changes support a simple dominant gain of function.
P2860
Q21092845-24C8859F-9447-4C78-B74B-2D4E717C3664Q23912810-2D904B8A-A5A3-42D1-9663-B88055C5504EQ24799882-64FEF692-4E84-4856-A922-A636D6ED6FA7Q26775096-3A89F3A8-98FB-4087-86AC-B019383D2902Q27301289-9A65EFA4-A094-482D-BD4E-BE0A4584D4DAQ27319287-96F70D0C-AB0A-4478-816E-CBBC29A17AD4Q28072937-14E8D3D6-DC74-48B9-89E2-6F43B1E4DED1Q28281904-7EEE5359-227F-412D-8A3D-A62F044A5BA2Q28389607-94C73ACE-5437-4F72-8AC0-E9B5B1BD1AFFQ28390800-C2098B35-4620-4FB5-8038-A87CFCB7018DQ28391627-6C523EAE-7205-49B2-BAAF-3C6A9053B409Q28394301-7B0BF982-1B37-4404-9F9E-0167CCEE320FQ28394803-41AB264C-6D1C-45E0-B576-F4CAC1E932F2Q28394979-A6E3C551-F357-4946-8C52-EC12786381E0Q28469280-4FF3BC60-8F97-4261-8B4F-76026682671FQ28479035-EFCA270E-C20E-4E54-A28D-EC8308B7A3C6Q28580488-D2C27B55-3893-40A7-ABAB-75165E9794ABQ28661435-FEC57D92-74D6-4E25-8BF8-CBB5739EDBD4Q28748849-840D4AA6-6CE2-4F4A-915F-CAEC39E8D3E2Q31032933-443068E9-3FBE-45E7-A4DA-F34588560C42Q33291754-44EAB455-E1FD-430F-99D7-651F259E188DQ33609937-C424DA33-B540-4311-9006-CC041F978328Q33617333-D2BA675A-7FCD-42CE-9C8F-1C6895DAE578Q33790829-26690912-E22D-4B94-AE94-4FF1606F02BCQ33900572-FA389E76-2CCC-48C4-AEBB-6B952BA754E0Q33908482-6EAC909C-8AE4-4DFF-A532-C2CDA520D4DBQ33967163-4E506B47-2706-4424-8D3D-FD27BC7E2901Q34009621-0D2CB85A-140F-441E-9223-A577876B59DCQ34140579-51DE6BCC-D102-49E7-81D4-C3B2E3A4FE14Q34278252-397F4417-1E38-4D0D-A7B3-1C791BAB4EB2Q34382326-6BD984FB-A26E-4876-84A7-AAADCCCA807FQ34392509-B85D90B5-6702-4988-8074-1F0B75F72C28Q34431341-307E9A8A-D6B6-40EF-93D7-A259653D74F9Q34435001-C1D67DC7-0E1D-4661-AD07-92D58968D428Q34472800-AC5145CD-F8D6-40B5-B2EA-C5ABD7AE9822Q34829422-96332578-47E0-40AE-95EB-E3DFAC18DFE6Q34994813-CAB5C6C3-AF96-487C-B317-2100C741796AQ35014895-44600CD3-965C-4D8E-B486-F678B65AF94CQ35024695-5858E297-1B36-46F9-8038-4B4E2DF66B5BQ35056067-311FCAAD-92A5-4853-8E97-BF2DCDCC5C6B
P2860
Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Specific progressive cAMP redu ...... ngton's disease knock-in mice.
@en
Specific progressive cAMP redu ...... ngton's disease knock-in mice.
@nl
type
label
Specific progressive cAMP redu ...... ngton's disease knock-in mice.
@en
Specific progressive cAMP redu ...... ngton's disease knock-in mice.
@nl
prefLabel
Specific progressive cAMP redu ...... ngton's disease knock-in mice.
@en
Specific progressive cAMP redu ...... ngton's disease knock-in mice.
@nl
P2093
P50
P356
P1476
Specific progressive cAMP redu ...... ngton's disease knock-in mice.
@en
P2093
Elena Ivanova
Elisa Fossale
Francesca Persichetti
Ihn Sik Seong
Silvia Gines
Vanessa C Wheeler
P304
P356
10.1093/HMG/DDG046
P577
2003-03-01T00:00:00Z